The pharmaceutical industry is highly volatile, with promising lead candidates making or breaking a company’s year.
Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies and research organizations to enable them to develop the next leading drug in the market, observes GlobalData, a leading data and analytics company.
The $8.5 billion agreement between AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) to co-develop AstraZeneca’s Lynparza (olaparib) for multiple cancer types puts the two companies at the top for strategic alliance spending for 2017. AstraZeneca just clinched the top spot from Merck with its development deals with Pieris Pharmaceuticals (Nasdaq: PIRS) and MedImmune.
Lisa Marris, healthcare analyst at GlobalData, comments: “Despite this, Merck has had an arguably more successful year. It more than quadrupled its alliance deal values since 2016, and if its subsidiaries are added to the equation, its 2017 deal values rise to $9.5 billion, an increase of 248% from 2016, whereas AstraZeneca and its subsidiaries stayed almost stagnant at $11 billion.
Also big year for Pieris
Pieris Pharmaceuticals also saw a good year, making alliances in 2017 worth more than 35 times those it made in 2016. However, it is unlikely to do as well this year, as the 2017 value was primarily due to its $2.2 billion co-development deal with AstraZeneca, alongside a $1.8 billion licensing agreement with Frances’ Servier.
Ms Marris continues: “The development agreement with AstraZeneca will help Pieris enhance its inhaled drug candidates for respiratory diseases, whereas the collaboration with Servier will advance Pieris’ immune-oncology programs, led primarily by PRS-332, a PD-1-targeting bispecific checkpoint inhibitor.”
[NB: Not included in the GlobalData analysis, just last week, Pieris signed up another deal, with a potential of $1.2 billion in upfront and milestone payments with Seattle Genetics.]
Allergan and Novartis both experienced slower years than 2016, with decreases in partnership and licensing deal value by 44% and 5%, respectively. However, both companies still closed big deals in 2017. Allergan entered into a $2.8 billion licensing agreement with Assembly Bioscience to acquire microbiome gastrointestinal (GI) development programs. Novartis entered into almost double the number of deals it had in 2016, and closed two $1 billion deals in cardiovascular and eye indications with Ionis Pharma and Tribos, respectively.
GlobalData expects that 2018 is likely to be Merck’s year in terms of research and development collaboration.
Source: The Pharma Letter
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
